Halozyme Appoints Michael LaBarre CSO
This article was originally published in Scrip
Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, has promoted Dr. Michael J. LaBarre to chief scientific officer, succeeding Dr. Michael Shepard, who has been appointed a research fellow for the company. The move broadens LaBarre's responsibilities to include R&D of early pipeline assets, in addition to his role managing product development and Halozyme's Enhanze platform partnerships. Prior to joining Halozyme in 2008, he was vice-president, product development at Paramount BioSciences LLC; director, analytical and protein biochemistry, discovery research at Biogen Idec; and director analytical and formulation sciences, research and development at Idec Pharmaceuticals.